Sounds like Richard Pazdur, head of Oncology Center of Excellence, might want to be looking for other employment.

If Dr. Prasad, the oncologist & biostatician, is directly handling Leronlimab's path, which i do not see why he would not be, given our data, then that would be excellent.

Excited, frustrated, irritatable, impatient -- shareholder

But sayin it again:

We just might score one hell of an outstanding FDA press release.....